drugset / Trial / NCT06682780
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.
Timeline
- Start
- 2025-09-17
- Primary completion
- 2028-12-25
- Completion
- 2029-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | LM-2417 | Unknown | — | Intravenous |
| Subject | Lenvatinib | Small molecule | — | Oral |
| Subject | Niraparib | Small molecule | — | Oral |
| Subject | Tirelizumab | Monoclonal antibody | — | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |